A share price of Fulcrum Therapeutics Inc [FULC] is currently trading at $9.74, up 6.22%. An important factor to consider is whether the stock is rising or falling in short-term value. The FULC shares have gain 4.28% over the last week, with a monthly amount glided 9.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Fulcrum Therapeutics Inc [NASDAQ: FULC] stock has seen the most recent analyst activity on May 20, 2024, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $23. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 13, 2024, and set its price target to $14. On September 25, 2023, Goldman initiated with a Neutral rating and assigned a price target of $5 on the stock. H.C. Wainwright upgraded its rating to a Buy and increased its price target to $14 on August 23, 2023. Stifel upgraded its rating to a Buy and raised its price target to $11 on August 22, 2023. Goldman downgraded its rating to Neutral for this stock on May 04, 2023, and downed its price target to $3. In a note dated March 10, 2023, H.C. Wainwright downgraded an Neutral rating on this stock and revised its target price from $20 to $6.
Fulcrum Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.14 and $13.70. Currently, Wall Street analysts expect the stock to reach $18.4 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $9.74 at the most recent close of the market. An investor can expect a potential return of 88.91% based on the average FULC price forecast.
Analyzing the FULC fundamentals
Trailing Twelve Months sales for Fulcrum Therapeutics Inc [NASDAQ:FULC] were 81.63M which represents 8990.91% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.4%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.08 and Total Capital is -0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.21 points at the first support level, and at 8.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.08, and for the 2nd resistance point, it is at 10.43.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Fulcrum Therapeutics Inc [NASDAQ:FULC] is 22.07. On the other hand, the Quick Ratio is 22.07, and the Cash Ratio is 6.83. Considering the valuation of this stock, the price to sales ratio is 7.45, the price to book ratio is 2.21.
Transactions by insiders
Recent insider trading involved Tourangeau Greg, Principal Accounting Officer, that happened on May 07 ’24 when 236.0 shares were sold. Vice President, Finance, Tourangeau Greg completed a deal on Mar 08 ’24 to sell 4884.0 shares. Meanwhile, Sapir Alex bought 43360.0 shares on Mar 04 ’24.
